The global influenza vaccine market, valued at $8.96 billion in 2024, is projected to reach $13.32 billion by 2030 with a 7% annual growth rate. Growth is fueled by rising public health awareness, an expanding elderly population, government immunization programs, and ongoing vaccine research. Innovations in vaccine technology, including cell-based and mRNA vaccines, along with increased accessibility through public campaigns, are key drivers. North America leads the market, while Asia Pacific is expected to grow fastest, supported by large populations and improved healthcare infrastructure.
Royalty Pharma reported a 6% increase in Portfolio Receipts to $773 million in Q2 2026, driven by a 14% rise in Royalty Receipts from key drugs like Tremfya and Evrysdi. The company acquired new royalty interests, including AstraZeneca’s cliramitug, ...
The FTSE 100 fell 30 points to 10,838, dragged down by AstraZeneca's 9.3% drop following reports of merger talks with Bristol Myers Squibb, which raised concerns over strategic fit and antitrust issues. Commodity giants like Rio Tinto and BP also dec...
